Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients

Infection in ICU Clinical Trial

— ANTHICUS  

Official title:

Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A Prospective, Observational, Multicenter Study (ANTHICUS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00543894
• Other study ID #: SRP-HB-MER-2005/1
• Status: Completed
• Phase: N/A
• First received: October 11, 2007
• Last updated: August 11, 2008
• Start date: February 2006

Study information

• Verified date: June 2007
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Observational

Clinical Trial Summary

Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A prospective, observational, multicenter study (ANTHICUS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with hospital-acquired infections and hospitalised in the ICU at one moment of their hospital stay

• Hospital-acquired infections accounting for eligibility are:

• nosocomial pneumonia (including ventilator-associated pneumonia)

• bacteremia

• intra-abdominal infections

• urosepsis

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Communicable Diseases
• Cross Infection
• Infection
• Infection in ICU

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Outcome

Type	Measure	Description	Time frame	Safety issue
Secondary	the frequency of appropriate antibiotic therapy (defined as the use of antibiotic(s) with "in vitro" efficacy against the identified pathogens responsible for the infection)
Secondary	the frequency of "the strategy of de-escalation" according to the culture results